Plasmacytoid dendritic cells during COVID-19: Ally or adversary?

Cell Rep. 2022 Jul 26;40(4):111148. doi: 10.1016/j.celrep.2022.111148. Epub 2022 Jul 14.

Abstract

Plasmacytoid dendritic cells (pDCs) are specialized cells of the immune system that are thought to be the main cellular source of type I interferon alpha (IFNα) in response to viral infections. IFNs are powerful antivirals, whereas defects in their function or induction lead to impaired resistance to virus infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. IFN production needs to be controlled, because sustained IFN production can also have detrimental effects on disease outcome. As such, pDCs are likely important for acute antiviral protection against SARS-CoV-2 infection but could potentially also contribute to chronic IFN levels. Here, we provide a historical overview of pDC biology and summarize existing literature addressing their involvement and importance during viral infections of the airways. Furthermore, we outline recent reports focused on the potential role of pDCs during SARS-CoV-2 infection, as well as the potential for this cellular subset to impact COVID-19 disease outcome.

Keywords: COVID-19; CP: Immunology; CP: Microbiology; SARS-CoV-2; antiviral responses; inflammation; plasmacytoid dendritic cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • COVID-19*
  • Dendritic Cells
  • Humans
  • Interferon Type I*
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Interferon Type I